Enveric Biosciences, Inc.
ENVB· Nasdaq
ENVBEnveric Biosciences, Inc.
Filed Mar 31, 2023 · 10-K · 90 days after period end · 0001493152-23-010431
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $9.06M |
| Net Income | -$8.68M | -$42.11M | -$2.55M | -$2.53M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end
